Literature DB >> 26057954

CAR-T field booms as next-generation platforms attract big players.

Chris Morrison.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26057954     DOI： 10.1038/nbt0615-571

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Developers seek to finetune toxicity of T-cell therapies.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2014-12       Impact factor: 54.908

2.  T-cell therapy at the threshold.

Authors:  Carl June; Steven A Rosenberg; Michel Sadelain; Jeffrey S Weber
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908
  2 in total
  5 in total

1.  Off-the-shelf CAR-T therapy induces remission in child with ALL.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2016-01       Impact factor: 54.908

2.  CAR-T cells forge ahead, Novartis reorganizes.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2016-11-08       Impact factor: 54.908

Review 3.  A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.

Authors:  Erhao Zhang; Hanmei Xu
Journal:  J Hematol Oncol       Date:  2017-01-03       Impact factor: 17.388

Review 4.  Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.

Authors:  Erhao Zhang; Jieyi Gu; Hanmei Xu
Journal:  Mol Cancer       Date:  2018-01-12       Impact factor: 27.401

5.  Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.

Authors:  Erhao Zhang; Jieyi Gu; Jianpeng Xue; Chenyu Lin; Chen Liu; Mengwei Li; Jingchao Hao; Sarra Setrerrahmane; Xiaowei Chi; Weiyan Qi; Jialiang Hu; Hanmei Xu
Journal:  J Hematol Oncol       Date:  2018-03-20       Impact factor: 17.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.